Abstract

Standard chemotherapy has a poor outcome in adult patients with high-risk acute lymphoblastic leukaemia (ALL). Allogeneic haemopoietic progenitor transplant (alloSCT) is the treatment of choice, and SCT with alternative progenitors should be considered in the absence of a matched sibling donor. There is great heterogeneity in the data on unrelated SCT for adult patients with high-risk ALL. Many studies include both paediatric and adult patients, or provide combined data from ALL and acute myeloid leukaemia (AML) patients. Moreover, the follow-up of the reported series is highly variable, and the definition of high-risk criteria varies from one study to another. The reported disease-free survival (DFS) for adult ALL patients ranges from 30 to 70%, and leukaemia relapse (14–47%) is an important cause of treatment failure. Despite great improvements in recent years, transplant-related mortality (TRM) from unrelated SCT (USCT) remains unacceptably high (29–36%). The human leukocyte antigen (HLA) disparity in the unrelated donor setting with a high incidence of graft-versus-host disease (GvHD) and delayed immunological reconstitution with a high incidence of infectious events in the unrelated cord blood SCT are the most important causes of morbidity and mortality in unrelated transplants. Disease status at transplant and the presence of acute and/or chronic GvHD are the most important factors determining relapse in high-risk ALL adult patients undergoing USCT.

Keywords

Acute lymphoblastic leukaemia, allogeneic haemopoietic progenitor transplant, unrelated cord-blood transplant, adult, unrelated donor haemopoietic stem cell transplant

Disclosure: The authors have no conflicts of interest to declare.

Received: 22 May 2009 Accepted: 26 June 2009
Correspondence: Christelle Ferrà, Department of Clinical Haematology, Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, C/ Canyet s/n, 08916-Badalona, Spain. E: cferra@iconcologia.net

The outcome of adults with high-risk acute lymphoblastic leukaemia (ALL) features at diagnosis, slow responders or those with recurrent disease is poor with standard chemotherapy. Autologous stem cell transplantation (ASCT) has not demonstrated a clear advantage over chemotherapy for ALL patients in complete remission due to the high relapse rate, and allogeneic SCT (alloSCT) – even if associated with a higher transplant-related mortality (TRM) – remains the best therapeutic option for such high-risk ALL patients. In standard-risk ALL, the role of alloSCT remains uncertain in patients in first complete remission (CR). However, the UKALL/XI/Eastern Cooperative Oncology Group (ECOG) 2993 and the Dutch–Belgian Cooperative Trial Group for Hematology Oncology (HOVON)-18 ALL/HOVON-37 ALL studies have recently shown a survival advantage for those patients receiving a sibling-matched alloSCT. The expected disease-free survival (DFS) in high-risk adult patients is between 30 and 40%, and in most centres such patients are considered for an alternative donor SCT if a matched-sibling donor is not available, which reportedly occurs in about two-thirds of patients. Alternative haemopoietic sources can be partially human leukocyte antigen (HLA)-matched family donors, unrelated donors (UDs) or unrelated cord blood units, the latter having emerged as an option for unrelated SCT (USCT) even in adult patients. Despite some groups having reported a similar outcome for related and unrelated SCT in adult ALL patients, there seems to be a trend towards a poorer outcome in USCT due to a higher TRM. However, long-term results of adult patients receiving an alloSCT from an alternative source are scarce. The best choice of unrelated progenitor source and the best timing for the USCT remain matters of concern for many haematologists, especially in adult patients.

Indication for Unrelated Stem Cell Transplantation in Adult Acute Lymphoblastic Leukaemia

High-risk criteria in ALL patients include disease stage beyond the first CR and patients with first remission if they have poor-risk cytogenetics ([t(9;22), t(4;11), t(1;19), complex karyotype [more than four cytogenetic abnormalities] and low hypodiploidy/near triploidy], a slow response to induction chemotherapy (more than four weeks to achieve the first CR), failure to achieve complete CR after one induction course, leukocytosis at diagnosis (>30x10⁹/l in B-precursor ALL or >100x10⁹/l in T-cell ALL) or age >35 years. Moreover, a significant level of minimal residual disease (MRD) has recently been associated with a poor outcome despite good prognostic features at diagnosis and the patients being in morphological remission. Identification of biologically distinct subsets of ALL through cytogenetic, molecular and gene expression studies, as well as investigation of MRD and host pharmacogenomics, offers promising avenues of research. Integration of molecular tools into clinical practice will ultimately allow more precise risk stratification and individualised treatment planning. In a recent report, USCT was clearly
Haematological Malignancies

proved to be superior to conventional chemotherapy in the pre-imatinib era for patients with Philadelphia-chromosome-positive (Ph+). ALL lacking a matched related donor. The phase of the disease at transplant is one of the most important factors influencing relapse in the unrelated transplant setting for both USCT and unrelated cord blood SCT. Advanced disease status is associated not only with a higher relapse rate but also with a higher TRM. The follow-up of 609 adult patients after relapse of ALL in the UKALL12/ECOG 2993 study revealed that only a very highly selected subgroup of patients were able to receive SCT after relapse, resulting in a superior overall survival (OS) (16% for matched unrelated and 23% for sibling allograft SCT) than those receiving chemotherapy alone (4%). The grim prognosis of adult patients with high-risk ALL after relapse justifies considering alternative donor transplants in first CR if a sibling donor is lacking. The prevention of relapse remains the most important goal for long-term survival in ALL patients. Moreover, the detection of residual disease during the post-transplant period may be useful to diagnose recurrent disease early, allowing early therapeutic interventions.

**Stem Cell Source**

**Unrelated Donor Stem Cell Transplant**

For many years, bone marrow has been the stem cell source of choice for unrelated transplants. However, the mobilised peripheral blood stem cell (PBSC) has been widely adopted by many centres as the preferred unrelated stem cell source. Some data have pointed out a worse prognosis for patients receiving PBSC versus bone marrow graft in the unrelated setting for ALL due to a higher incidence of chronic graft-versus-host disease (GvHD) in former patients. Some groups have explored T-cell depletion of unrelated PBSC or bone marrow without showing a clear advantage in survival for T-cell-depleted grafts. Cornilissen et al. reported their experience with unrelated bone marrow transplant provided by the National Marrow Donor Program (NMDP) collection centres for transplant in adult patients with ALL, and concluded that the main factors for a better DFS were first CR at SCT, absence of HLA-A, -B or DRB1 mismatch, negative cytomegalovirus (CMV) serology and a shorter interval from diagnosis to transplantation. For patients in first CR, the OS (95% confidence interval [CI]), relapse rate and TRM at two years were 40% (13%), 6% (7%) and 54% (13%), respectively. These data included patients from an early period (1988–1999), but more recent reports incorporating high-resolution typing HLA methods for HLA-A, -B and -C have shown better expected rates. These data included patients from an early period (1988–1999), but more recent reports incorporating high-resolution typing HLA methods for HLA-A, -B and -C have shown better expected rates. Moreover, some studies included both AML and ALL or a variable proportion of paediatric patients. Finally, the OS, DFS and TRM were estimated at different periods of time (one to five years or more) and a short period follow-up underestimated late TRM (see Table 1). Most comparative studies of UCB-SCT versus bone marrow SCT for leukaemia from UDs have shown similar outcomes. Initial comparisons between UCB-SCT and UD-SCT (including only bone marrow SCT) showed that patients receiving an UCB-SCT had a delayed neutrophil and platelet engraftment and a lower incidence of acute GvHD, in spite of a greater HLA mismatch between the patient and the graft. However, the survival rate was similar when a comparison of procedures was performed at an early stage for transplantations with cord blood progenitors in adult patients. Three major studies have compared the outcome of paediatric patients with ALL after USCT, focusing on the haematopoietic stem cell source. In paediatric patients, a better outcome for patients receiving a fully matched UD bone marrow transplant has been reported, and this was confirmed by some groups in an adult population. In terms of adult patients, Atsuta et al. carried out a large study using the Japanese registries to explore the impact of stem cell source (bone marrow or umbilical cord) for adult patients with acute leukaemia, making a disease-specific comparison. In the ALL group, there were no differences in terms of TRM, OS or DFS when eight out of eight matched bone marrow or UCB were compared. There was a trend towards a higher cumulative incidence of relapse in UCBC recipients. As expected, UCB-SCT was associated with a lower incidence of chronic (especially extensive) and acute GvHD. The recurrence of the primary disease was the leading cause of death for high-risk ALL patients. Other studies did not find differences in relapse rate when UCB-SCT and UD-SCT were compared.

**Unrelated Cord Blood Stem Cell Transplant**

Unrelated cord blood was initially introduced as an alternative source for SCT for paediatric patients, but more recently it has been considered for adult patients. Initial experiences with unrelated cord blood stem cell transplant (UCB-SCT) showed the importance of receptor age, the cell dose infused and the degree of HLA disparity in transplant outcome. Cord blood progenitors are more permissive with HLA disparities, and it is standard practice to allow zero to two HLA mismatches using low-resolution typing methods for HLA-A and -B and high-resolution molecular typing for HLA-DRB1. In contrast, recommendation for unrelated bone marrow or PBSC transplants is more restrictive and considers zero to one mismatch using high-resolution molecular typing of eight or 10 alleles (HLA-A, -B, -C, -DRB1, -DP). The use of high-resolution typing by sequencing for HLA-A, -B, -C and -DQ has shown that the degree of mismatching in UCB-SCT is even higher than expected. However, it does not seem to have a significant impact on the long-term clinical outcome in the UCB-SCT setting.

**Comparison of Outcome Between Unrelated Donor Transplant and Unrelated Cord Blood Transplant**

Many studies have described the outcome of UCB-SCT and compared the results with those from UD-SCT. In most studies comparing the two sources, the proportion of patients with more advanced disease or with poore-prognosis leukaemia was higher in the UCB-SCT group. Moreover, some studies included both AML and ALL or a variable proportion of paediatric patients. Finally, the OS, DFS and TRM were estimated at different periods of time (one to five years or more) and a short period follow-up underestimated late TRM (see Table 1). Most comparative studies of UCB-SCT versus bone marrow SCT for leukaemia from UDs have shown similar outcomes. Initial comparisons between UCB-SCT and UD-SCT (including only bone marrow SCT) showed that patients receiving an UCB-SCT had a delayed neutrophil and platelet engraftment and a lower incidence of acute GvHD, in spite of a greater HLA mismatch between the patient and the graft. However, the survival rate was similar when a comparison of procedures was performed at an early stage for transplantations with cord blood progenitors in adult patients. Three major studies have compared the outcome of paediatric patients with ALL after USCT, focusing on the haematopoietic stem cell source. In paediatric patients, a better outcome for patients receiving a fully matched UD bone marrow transplant has been reported, and this was confirmed by some groups in an adult population. In terms of adult patients, Atsuta et al. carried out a large study using the Japanese registries to explore the impact of stem cell source (bone marrow or umbilical cord) for adult patients with acute leukaemia, making a disease-specific comparison. In the ALL group, there were no differences in terms of TRM, OS or DFS when eight out of eight matched bone marrow or UCB were compared. There was a trend towards a higher cumulative incidence of relapse in UCBC recipients. As expected, UCB-SCT was associated with a lower incidence of chronic (especially extensive) and acute GvHD. The recurrence of the primary disease was the leading cause of death for high-risk ALL patients. Other studies did not find differences in relapse rate when UCB-SCT and UD-SCT were compared.

The disadvantages of using UCB as a haematopoietic source are the limited number of stem cells in the unit, the impossibility of performing cellular therapy with lymphocytes belonging to the donor, the delayed haematological recovery and the delayed immune reconstitution. However, a higher infectious vulnerability may be compensated by a lower risk of GvHD. Due to slower haematopoietic and immune reconstitutions after UCB-SCT, severe infections are more frequent after UCB-SCT than after non-T-cell-depleted progenitors in UD-SCT.
Unrelated Transplants for High-risk Adult Acute Lymphoblastic Leukaemia

Table 1: Relevant Studies on Outcome of Adult Acute Lymphoblastic Leukaemia Patients with Unrelated Stem Cell Transplantation

<table>
<thead>
<tr>
<th>Source</th>
<th>No. Age</th>
<th>Donor</th>
<th>Stem Cell Source</th>
<th>ALL (%)</th>
<th>GvHD Prophylaxis</th>
<th>aGvHD (%)</th>
<th>cGvHD (%)</th>
<th>TRM (%)</th>
<th>RR (%)</th>
<th>DFS (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rubenstein, 1998</td>
<td>562 (0–58) Unrelated</td>
<td>USCT</td>
<td>177 (47%)</td>
<td>Several schedules</td>
<td>42</td>
<td>25</td>
<td>–</td>
<td>24</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Bornhäuser, 2000</td>
<td>79 (4–58) Unrelated</td>
<td>PBSC</td>
<td>10 (13%)</td>
<td>Several schedules</td>
<td>47</td>
<td>27</td>
<td>–</td>
<td>38–8</td>
<td>47 (1)</td>
<td></td>
</tr>
<tr>
<td>Cornelissen, 2001</td>
<td>127 (&gt;17) Unrelated</td>
<td>BM</td>
<td>127 (100%)</td>
<td>Several schedules</td>
<td>50</td>
<td>48 (extensive)</td>
<td>–</td>
<td>19</td>
<td>40–32 (2)</td>
<td></td>
</tr>
<tr>
<td>Sanz, 2001</td>
<td>22 18–46 Unrelated</td>
<td>CB</td>
<td>6 (27%)</td>
<td>CsA + MTX</td>
<td>32</td>
<td>40 (extensive)</td>
<td>43</td>
<td>–</td>
<td>53 (1)</td>
<td></td>
</tr>
<tr>
<td>Rocha, 2004</td>
<td>682 15–59</td>
<td>Unrelated</td>
<td>BM</td>
<td>320 (47%)</td>
<td>CsA – MTX**</td>
<td>26</td>
<td>30</td>
<td>44</td>
<td>23</td>
<td>33 (2)</td>
</tr>
<tr>
<td>Laughlin, 2004</td>
<td>600 16–60</td>
<td>Unrelated</td>
<td>Matched BM</td>
<td>144 (24%)</td>
<td>Several schedules</td>
<td>48</td>
<td>35</td>
<td>46</td>
<td>23</td>
<td>33 (3)</td>
</tr>
<tr>
<td>Takahashi, 2004</td>
<td>113 16–53</td>
<td>Unrelated</td>
<td>CB</td>
<td>23 (20%)</td>
<td>CsA + MTX</td>
<td>27 (III–IV)</td>
<td>24 (extensive)</td>
<td>9</td>
<td>16</td>
<td>74 (2)</td>
</tr>
<tr>
<td>Kiehl, 2004</td>
<td>221 17–62</td>
<td>Related/ unrelated</td>
<td>PBSC, BM</td>
<td>221 (100%)</td>
<td>CsA + MTX</td>
<td>30</td>
<td>–</td>
<td>43</td>
<td>–</td>
<td>29 (3)</td>
</tr>
<tr>
<td>Barker, 2005</td>
<td>23 13–53</td>
<td>Unrelated</td>
<td>CB x 2</td>
<td>8 (35%)</td>
<td>Several schedules</td>
<td>65</td>
<td>25</td>
<td>22</td>
<td>–</td>
<td>57 (1)</td>
</tr>
<tr>
<td>Magro, 2001</td>
<td>27 16–60</td>
<td>Unrelated</td>
<td>CB</td>
<td>14 (52%)</td>
<td>CsA + PDN</td>
<td>74 (all)</td>
<td>20 (limited)</td>
<td>30</td>
<td>20</td>
<td>56 (4)</td>
</tr>
<tr>
<td>Chim, 2007</td>
<td>108 15–56</td>
<td>Related/ unrelated</td>
<td>BM</td>
<td>108 (100%)</td>
<td>CsA + MTX</td>
<td>32</td>
<td>–</td>
<td>15</td>
<td>64</td>
<td>41 (15)</td>
</tr>
<tr>
<td>Lee, 2007</td>
<td>201 15–52</td>
<td>Related/ unrelated</td>
<td>PBSC, BM</td>
<td>201 (100%)</td>
<td>CsA+FK506 + MTX</td>
<td>41</td>
<td>50</td>
<td>21</td>
<td>36</td>
<td>50 (5)</td>
</tr>
<tr>
<td>Bishop, 2007</td>
<td>260 &gt;18</td>
<td>Autologous/ unrelated</td>
<td>BM</td>
<td>101 (100%)</td>
<td>Several schedules</td>
<td>ND</td>
<td>–</td>
<td>9</td>
<td>58</td>
<td>29 (5)</td>
</tr>
<tr>
<td>Marks, 2008</td>
<td>169 16–59</td>
<td>Unrelated</td>
<td>PBSC/BM</td>
<td>169 (100%)</td>
<td>Several schedules</td>
<td>50</td>
<td>38–43</td>
<td>36–41</td>
<td>15–20</td>
<td>38 (5)</td>
</tr>
<tr>
<td>Fielding, 2009</td>
<td>31 15–60</td>
<td>Unrelated</td>
<td>PBSC/BM</td>
<td>31 (100% Ph1+)</td>
<td>CsA + MTX</td>
<td>50</td>
<td>–</td>
<td>39</td>
<td>–</td>
<td>36 (5)</td>
</tr>
<tr>
<td>Atsuta, 2009</td>
<td>336 16–59</td>
<td>Unrelated</td>
<td>BM</td>
<td>336 (100%, 28% Ph1+)</td>
<td>Several schedules</td>
<td>42</td>
<td>30</td>
<td>24</td>
<td>24</td>
<td>51 (2)</td>
</tr>
<tr>
<td>Ringdén, 2009</td>
<td>4,099 &gt;18</td>
<td>Related/ unrelated</td>
<td>PBSC/BM</td>
<td>672 (16%)</td>
<td>Several schedules</td>
<td>52</td>
<td>49</td>
<td>31–41</td>
<td>23–52</td>
<td>46–10 (5)</td>
</tr>
</tbody>
</table>

* >70% of cases; ** >95% of cases.

ALL = acute lymphoblastic leukaemia; aGvHD = acute graft-versus-host disease; cGvHD = chronic graft-versus-host disease; Phi + = Philadelphia-chromosome-positive; USCT = unrelated stem cell transplantation; BM = bone marrow; CB = cord blood; mmBM = mismatched bone marrow; T-DBM = T-cell-depleted bone marrow; PDN = prednisone; ND = not declared; PBSC = peripheral blood stem cell; CSA = cyclosporine A; MTX = methotrexate; FK506 = tacrolimus.

especially within 100 days after transplantation. 13,17,24,26,27 Parody et al. compared the infectious events in UCB-SCT and UD-SCT, and concluded that UCB-SCT recipients had a similar risk of death due to infection if an accurate selection of the cord blood unit was performed. With a median follow-up of three years, UCB-SCT recipients had a higher risk of developing any severe infection (85 versus 69% in bone marrow/peripheral blood SCT recipients). However, at three years the risks of severe bacterial infection or other infections were similar in the UCB-SCT and UD-SCT. In addition, the 100-day and three-year incidences of infection-related mortality did not differ among groups.

In contrast to the adult setting, UCB-SCT seems to present a similar risk of serious infections than unmanipulated bone marrow in the paediatric population. 13,17,24,26,27 A higher stem cell dose has shown to improve the outcome of acute leukaemia patients receiving SCT with progenitors from unrelated bone marrow (nucleated cells [NC] >3.65x10^9/kg)52 or umbilical cord blood (NC >2x10^9/kg). 53 In contrast, in UCB-SCT, the importance of an HLA match has been less evident in many reports than that of cell dose. 13,17,24,26,27 The HLA disparity will be only partially compensated by the progenitor cellular dose, 13,17,24,26,27 and in some studies may be associated with a lower risk of leukaemia relapse. However, in UCB-SCT, even if the procedure is not so greatly compromised by HLA disparity, this will also be associated with a poorer outcome due to a higher risk of GvHD and TRM without any survival advantage. 13,17,24,26,27
Haematological Malignancies

Conditioning Therapy

Traditionally, conditioning therapy including total body irradiation (TBI) has been associated with better DFS for ALL patients, especially in children. Busulfan-containing regimens have been associated with a higher TRM (basically hepatic sinusoidal obstructive syndrome and haemorrhagic cystitis). The higher relapse rate associated with chemotherapy conditioning has not been confirmed by all groups. There are no randomised studies comparing different conditioning therapies specifically for ALL. Some comparative studies included only a variable proportion of ALL patients and most were performed in the matched-sibling setting. Moreover, none of these comparative studies performed busulfan adjustment based on the drug plasma levels. Non-myeloablative conditioning regimens allow transplantation to be performed in patients who are not candidates for myeloablative therapies due to advanced age, co-morbidities or a previous myeloablative SCT. With this approach a graft-versus-leukaemia (GvL) effect may be obtained with acceptable toxicity in the related and unrelated settings.

The high incidence of disease relapse remains the main drawback of such an approach. Disease status at transplant and the presence of chronic GvHD are other main factors influencing relapse in this setting. However, for adults with ALL in first CR, reduced-intensity conditioning (RIC) allografting results in a promising DFS with acceptable TRM. In some groups, SCT with RIC has been followed by a double or multiple graft for UCB-SCT, a procedure that seems to be associated with a slightly higher incidence of GvHD and a possible improvement of the GvL effect. In vivo T-cell depletion is the most effective method for preventing GvHD after allograft, and in spite of a delayed immunological reconstitution this effect could decrease the TRM in UCB SCT. In addition, the T-cell depletion of the graft has been associated with a higher incidence of CMV and fungal infection in the unrelated bone marrow setting, and as thymoglobulin is commonly given as conditioning therapy for UCB-SCT patients, this could contribute to a high incidence of infections in UCB-SCT. On the other hand, as T-cell depletion could also contribute to relapse, this procedure is not routinely performed in high-risk ALL patients.

Graft-versus-leukaemia Effect

In ALL, the antileukaemic activity of GvHD has been traditionally considered weaker than for other haematological diseases. However, many authors have demonstrated the antileukaemic effect of chronic GvHD, either in children or in adult patients receiving a related or especially an UCB SCT, either with a myeloablative or RIC regimen. The reduced relapse rate is hampered by an increase in the non-relapse mortality and morbidity in long-term survivors, with severely impaired quality of life for patients presenting with the extensive form of the disease. Consequently, the GvL effect has been mostly evident in the limited type of chronic GvHD. This GvL effect of chronic GvHD has been pointed out as stronger for ALL patients with translocations (including Ph+ ALL) or normal diploid cytogenetics than for patients with deletions or numeric abnormalities. The presence of acute GvHD also had a positive impact in decreasing the relapse rate, but it is associated with a higher TRM and a decreased survival if it is severe. As the disease status at transplant and the presence of chronic GvHD are the main factors influencing relapse in adult patients with high-risk ALL after an unrelated transplant, the lower incidence of GvHD found in UCB-SCT could justify the trend for a higher relapse rate in patients receiving unrelated cord blood as the source of haematopoietic stem cells.

Conclusions

An alternative donor SCT should be considered for poor-prognosis adult ALL patients in first CR without a sibling donor. However, all unrelated transplant modalities are associated with high TRM. The disease status at transplant and the presence of GvHD are the main factors influencing relapse in adult patients with high-risk ALL after an unrelated transplant. A clear recommendation about which is the best conditioning therapy or even the best unrelated source does not exist. The particularities of patients, progenitor compatibility and cellularity (if unrelated cord blood progenitors) should be carefully considered prior to transplant. Finally, the time interval to obtain the unrelated haematopoietic progenitors should also be taken into account in the selection process.

---

2. Goldstone AH, Richards SM, Lazarus HM, et al., In adults with standard-risk acute lymphoblastic leukaemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL; EUCOS E2992), Blood, 2008;111:1827–33.
3. Ribera JM, Oriol A, Bethencourt C, et al., Comparison of intensive chemotherapy, autologous or allogeneic stem cell transplantation as postremission treatment for adult patients with high-risk acute lymphoblastic leukaemia: Results of the PETHEMA-ALL-93 trial, hematologica, 2005;92:1346–56.
14. Kiehl MG, Kraut L, Schwerdtfeger R, et al., Outcome of
43. Barker J, Weisdorf DJ, DeFor TE, et al., Transplantation of 2 partially HLA-matched umbilical cord transplant in two partially HLA-matched units, Bone Marrow Transplant, 2009 (Epub ahead of print).